Cargando…

Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents

IMPORTANCE: In the US, hepatocellular carcinoma (HCC), primarily associated with hepatitis C virus (HCV) infection, is the fastest rising cause of cancer-related death. Wider use of highly effective direct-acting antiviral agents (DAAs) substantially reduces the burden of chronic HCV infection, but...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qiushi, Ayer, Turgay, Adee, Madeline G., Wang, Xiaojie, Kanwal, Fasiha, Chhatwal, Jagpreet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675109/ https://www.ncbi.nlm.nih.gov/pubmed/33206188 http://dx.doi.org/10.1001/jamanetworkopen.2020.21173

Ejemplares similares

Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study
por: Chen, Qiushi, et al.
Publicado: (2019)

Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan
por: Chhatwal, Jagpreet, et al.
Publicado: (2019)

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India
por: Aggarwal, Rakesh, et al.
Publicado: (2017)

Projecting COVID-19 Mortality as States Relax Nonpharmacologic Interventions
por: Linas, Benjamin P., et al.
Publicado: (2022)

Association of Limited In-Person Attendance in US National Football League and National Collegiate Athletic Association Games With County-Level COVID-19 Cases
por: Toumi, Asmae, et al.
Publicado: (2021)

Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States
por: Chhatwal, Jagpreet, et al.
Publicado: (2023)

Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan
por: Zhuo, Yueran, et al.
Publicado: (2020)

Alcohol-Associated Liver Disease Mortality Rates by Race Before and During the COVID-19 Pandemic in the US
por: Kulkarni, Neeti S., et al.
Publicado: (2023)

Comparison of a multitarget blood test to ultrasound and alpha‐fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta‐analysis
por: Singal, Amit G., et al.
Publicado: (2022)

Outcomes in the Era of Interferon-Free Direct-Acting Antiviral Therapy After Liver Transplantation in Patients with Hepatitis C Virus and Hepatocellular Carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2021)

Barriers to Surveillance for Hepatocellular Carcinoma in a Multicenter Cohort
por: Parikh, Neehar D., et al.
Publicado: (2022)

Adding to the evidence base: Effectiveness of hepatocellular carcinoma surveillance in clinical practice
por: Pandya, Prashant, et al.
Publicado: (2017)

Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator
por: Adee, Madeline, et al.
Publicado: (2021)

Author Correction: Assessing cost-effectiveness of hepatitis C testing pathways in Georgia using the Hep C Testing Calculator
por: Adee, Madeline, et al.
Publicado: (2022)

Effectiveness of HCC surveillance programs using multitarget blood test: A modeling study
por: Chhatwal, Jagpreet, et al.
Publicado: (2023)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
por: Sonawane, Kalyani, et al.
Publicado: (2022)

Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
por: Sonawane, Kalyani, et al.
Publicado: (2022)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain’s Prisons: A Cost-Effectiveness Study
por: Dalgic, Ozden O., et al.
Publicado: (2019)

HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
por: La Manna, Gaetano
Publicado: (2018)

Artificial Neural Networks in Mammography Interpretation and Diagnostic Decision Making
por: Ayer, Turgay, et al.
Publicado: (2013)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Clinical efficacy of direct-acting antiviral therapy for recurrent hepatitis C virus infection after liver transplantation in patients with hepatocellular carcinoma
por: Ismail, Mohamed Saleh, et al.
Publicado: (2020)

Prevention of Prescription Opioid Misuse and Projected Overdose Deaths in the United States
por: Chen, Qiushi, et al.
Publicado: (2019)

Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States
por: Nguyen, Vy H., et al.
Publicado: (2022)

Synergistic Associations of PNPLA3 I148M Variant, Alcohol Intake, and Obesity With Risk of Cirrhosis, Hepatocellular Carcinoma, and Mortality
por: Kim, Hyun-seok, et al.
Publicado: (2022)

Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis
por: Klebanoff, Matthew J., et al.
Publicado: (2019)

Hepatitis C Screening and Treatment Program in Hungarian Prisons in the Era of Direct Acting Antiviral Agents
por: Werling, Klára, et al.
Publicado: (2022)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

PIN68 COVID-19 Simulator: An Interactive Tool to Inform COVID-19 Intervention Policy Decisions in the United States
por: Chhatwal, J., et al.
Publicado: (2020)

Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues
por: Tampaki, Maria, et al.
Publicado: (2018)

Analysis of a Simulation Model to Estimate Long-term Outcomes in Patients with Nonalcoholic Fatty Liver Disease
por: Chhatwal, Jagpreet, et al.
Publicado: (2022)

Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents
por: Cholankeril, George, et al.
Publicado: (2017)

HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly
por: Brozzetti, Stefania, et al.
Publicado: (2021)

When Can We Lift Non‐Pharmaceutical Interventions with the Availability of COVID‐19 Vaccine in the United States?
por: Chhatwal, Jagpreet, et al.
Publicado: (2021)

Cost-Effectiveness of Remdesivir for COVID-19 Treatment: What Are We Missing?
por: Chhatwal, Jagpreet, et al.
Publicado: (2022)

Reappraisal of the diagnostic value of alpha‐fetoprotein for surveillance of HBV‐related hepatocellular carcinoma in the era of antiviral therapy
por: Qian, Xiangjun, et al.
Publicado: (2020)

Long-acting antiviral agents for HIV treatment
por: Margolis, David A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_s1ptc0qmdj62ov959rhvm80mou